Factors affecting the experiences of drug use by adolescents in a Bangkok slum

The purpose of this research was to study the demography, financial status, social status, knowledge of amphetamines, perceived harmfulness of amphetamines, and life skills in the prevention of drug abuse in adolescents. The factors leading to drug use among young people were also studied. The study group was composed of 354 subjects aged 12 to 22 years, living in 2 slums in Bangkok. The research showed that about 7% of the sample group had used drugs before. Four percent had never used drugs, but someone had tried to talk them into using them. Almost 20% had friends who had used drugs, and 11% had friends who were still using drugs. About 13% of the adolescents in the study group had family members who used drugs and another 9% had family members who were still using drugs. In our study, we found that the most common drug group was amphetamines. On average, the participants had a low level of understanding about drug abuse, especially of the symptoms, side effects, and legal penalties. Most of the adolescents realized how harmful amphetamines and other drugs were and had a high degree life skills. Factors influencing adolescent drug use were (1) personal factors, such as monthly income/allowance and life skills; (2) family environment, such as drug abuse history in the family; and (3) social environment, such as a drug abuse history among friends. When studying the life skill factors of the adolescents, which is an independent factor capable of influencing the experience with drugs, the researchers found that the time spent with other members of the family and the family members' drug experiences were the only factors leading to life skills in the prevention of drug abuse in adolescents. In addition to letting children learn on their own, training them to acquire life skills is beneficial when faced with problematic situations. Creating relationships between adolescents and other members of the family, friends, and society can increase their life skills, diminishing the risk of drug abuse.

Safety, efficacy and extended duration of action of mixed amphetamine salts extended-release capsules for the treatment of ADHD

Stimulant medications have proven to be effective in reducing the core symptoms of hyperactivity, impulsivity and inattention and are considered the first line of therapy for patients with attention-deficit/hyperactivity disorder (ADHD). Mixed amphetamine salts extended-release capsules (MAS XR; Adderall XR, Shire Pharmaceuticals Group) include immediate-release pellets of mixed amphetamine salts that release the first half of the dose upon ingestion and delayed-release pellets that begin to release active drug approximately 4 h later. The MAS XR capsule contains the same 3:1 ratio of dextroamphetamine to levoamphetamine as do mixed amphetamine salts immediate-release tablets (MAS IR; Adderall), Shire Pharmaceuticals Group), and the bioavailability and pharmacokinetic profiles of MAS XR 20 mg are comparable to those with MAS IR 10 mg b.i.d. MAS XR has a rapid onset of action--within 1.5 h--and provides 12 h coverage. The efficacy, safety and extended duration of action of MAS XR have been established through clinical studies in school-age children, adolescents and adults.

Amphetamine-induced movement disorder

Recreational use of amphetamines is common in Australia and New Zealand when compared with other developed nations. The clinical effects are variable because of the potential of these drugs to increase the proportion of different biogenic amines in the central nervous system (CNS). The substances affected are adrenaline, noradrenaline, serotonin and dopamine. Movement disorders represent one of the less common presentations of amphetamine toxicity but one that health care workers should be aware of nonetheless.

[Pulmonary arterial hypertension due to the use of amphetamines as drugs or doping]

Pulmonary arterial hypertension (PAH) was diagnosed in three patients. All three had a history ofamphetamine consumption. The patients were a 48-year-old male drug addictwho had used intravenous amphetamine for more than 20 years, a 43-year-old man who had been administered intravenous amphetamines during a period of intensive cycling and a 34-year-old woman who regularly consumed amphetamine at dance festivals. All three patients received medicinal treatment. Amphetamines may lead to PAH due to the release of serotonin, which causes pulmonary vasoconstriction and the proliferation of smooth muscle cells. Due to the pathophysiology of amphetamine-induced PAH, other amphetamine derivatives such as methylenedioxymethamphetamine (ecstasy) and methylphenidate can be risk factors for PAH. These three cases show that PAH should be considered in patients who present with dyspnoea and a reduced exertion tolerance, and who are known to have a history of amphetamine use.

Long-term tolerability and effectiveness of once-daily mixed amphetamine salts (Adderall XR) in children with ADHD

OBJECTIVE

To evaluate the long-term tolerability and effectiveness of extended-release mixed amphetamine salts (MAS XR; Adderall XR) in children with attention-deficit/hyperactivity disorder (ADHD).

METHOD

This was a 24-month, multicenter, open-label extension of TWO placebo-controlled studies of MAS XR in children with ADHD aged 6 to 12 years. Subjects (N=568) began treatment with MAS XR 10 mg once daily, with 10-mg weekly dose increases to optimal effectiveness (maximum dose, 30 mg/d). Effectiveness was assessed with analysis of quarterly Conners Global Index Scale, Parent version (CGIS-P) scores. Tolerability was assessed by monitoring adverse events (AEs), vital signs, physical examinations, and serial laboratory tests.

RESULTS

Significant improvements (>30%, p < .001) in CGIS-P scores were maintained during long-term treatment. Treatment was well tolerated, and most AEs were mild. The most frequently reported drug-related AEs included anorexia, insomnia, and headache. The incidence of drug-related AEs increased with increasing MAS XR dose, suggesting a dose relationship. Changes in laboratory values and vital signs were modest and not clinically meaningful.

CONCLUSIONS

In children with ADHD, once-daily 10 mg-30 mg MAS XR was well tolerated and significant behavioral improvements were consistently maintained during 24 months of treatment.

Blood pressure changes associated with medication treatment of adults with attention-deficit/hyperactivity disorder

OBJECTIVE

To evaluate the effects of medications used in the treatment of adults with attention-deficit/hyperactivity disorder (ADHD) on blood pressure and pulse.

METHOD

Subjects were those with DSM-III-R-/DSM-IV-diagnosed ADHD enrolled in placebo-controlled studies of 5 different medications for ADHD. Cardiovascular data from these studies of both stimulants (methylphenidate, amphetamine compounds, pemoline) and nonstimulants (bupropion, desipramine) were reanalyzed for baseline-to-endpoint active-treatment or placebo effects on blood pressure and heart rate.

RESULTS

There were 125 subjects with a mean +/- SD age of 39 +/- 9 years. In general, active drug treatment for ADHD compared to baseline was associated with several statistically significant changes in systolic blood pressure (bupropion: +5.9 mm Hg, p < .05 by paired t test; amphetamine: +5.4 mm Hg, p < .05), diastolic blood pressure (desipramine: +7.1 mm Hg, p < .05), and heart rate (bupropion: +6.9 mm Hg, p < .05; amphetamine: +7.3 mm Hg, p < .05; methylphenidate: +4.5 mm Hg, p < .05). New-onset cases of systolic or diastolic hypertension (blood pressure > or = 140/90) were recorded in 8% (7/89) of placebo-treated subjects and 10% (9/89) of subjects receiving active medication, regardless of the class (stimulant, nonstimulant).

CONCLUSION

Both stimulant and nonstimulant catecholaminergic medications used in adults with ADHD are associated with minor, but statistically significant, changes in heart rate and blood pressure that were often observed in those receiving placebo. Given the minor pressor and chronotropic effect of these medications, adults with ADHD should have their blood pressure and heart rate checked at baseline and periodically during treatment.

Date-rape drugs scene in Poland

Since the beginnings of twenty-first century in Poland increasing number of reports about the drug-facilitated sexual assaults have been observed. Many drugs have been identified as so-called "date-rape drugs", because of their pharmacological properties, especially inducing amnesia. These drugs are used for the purpose of "drugging" unsuspected victims and than raping them. In a typical scenario, the perpetrator surreptitiously adds "date-rape drug" to the alcoholic or non-alcoholic beverage of an unsuspecting person, who is subsequently sexually assaulted while under the influence of this substance. Many victims do not report the incident until several days after the event or even do not report it at all. They report the incident so late after the events because they often have problems with remember the course of incident. It causes that victim is not reliable witness for justice. Detection of "date-rape drugs" in biological fluids is unequivocal evidence of perpetration. Analysis of biological fluids collected from victims of rapes for presence of drugs was rare in Poland up to now. The aim of this study is to show the use of "date-rape drugs" in Poland. Materials for this study were from the routine casework elaborated at the Institute of Forensic Research in Kraków. APCI-LC-MS methods were applied for screening of biological fluids (blood and/or urine) for amphetamine and its 6 analogues, for 12 substances from benzodiazepine group and for quantification of the detected drugs. HPLC-DAD was used as a screening method for wide range of medicinal drugs, and NCI-GC-MS methods for determination of ketamine and tetrahydrocannabinols (delta9-tetrahydrocannabinol, 9THC) and its metabolite (11-nor-carboxy-delta9-tetrahydrocannabinol, THCCOOH). In 2000-2004, the biological fluids taken from 33 persons, both sexually assaulted or perpetrators were analysed. In 2000 and 2002 not any case of this type was registered, in 2001 only two cases were recorded. After 2003 significant increase in the number of these cases was observed. Eleven and twenty cases involving "date-rape drugs" were submitted to the Institute in 2003 and 2004, respectively. The most common substances detected in analysed materials were amphetamine (in concentrations ranged from 10 to 85 ng/ml) and 9THC (0.36-1.4 ng/ml). Alcohol (0.27-2.3% per hundred), MDMA (8-201 ng/ml), benzodiazepines (oxazepam, nordazepam, estazolam), propranolol and lidocaine were also found in blood and urine specimens.

Die Wirksamkeit von Stimulanzien-Retardpräparaten bei Kindern und Jugendlichen mit ADHD - eine systematische Übersicht

Zusammenfassung: Stimulanzien sind das Mittel der Wahl zur pharmakologischen Behandlung einer Aufmerksamkeits-/Hyperaktivitätsstörung. Jedoch ist die Wirkdauer von schnell freisetzenden Präparaten oft nicht ausreichend. Mittlerweile wurden verschiedene retardierte Methylphenidat-, aber auch Amphetaminformen entwickelt, um die Probleme einer mehrfach täglichen Einnahme zu minimieren. Der Artikel stellt die klinischen Studien zu Wirksamkeit, Wirkdauer und Nebenwirkungsprofil verschiedener Stimulanzienformen dar. In der klinischen Anwendung sind die neuen Retard-Produkte wirkungsvolle Alternativen. Eine kontinuierliche mehrstufige Freisetzung des Wirkstoffs über den Tag verteilt nach einmaliger Medikamentengabe bietet Vorteile. Allerdings müssen Nebenwirkungen durch die verlängerte Wirkungsdauer genau beobachtet werden. Eine genauere Anpassung an die jeweiligen Erfordernisse der verschiedenen Tagesabschnitte und -bedürfnisse der Kinder und Jugendlichen ist schwierig. Die Erprobung von Titrierungsschemata unter Einbeziehung von schnell und verzögert freisetzenden Präparaten bleibt eine Aufgabe zukünftiger Forschung.

Pharmacological management of attention-deficit hyperactivity disorder

Pharmacotherapy is the most common intervention for attention-deficit hyperactivity disorder (ADHD). Stimulant medications are highly efficacious and are the gold-standard for treating the inattention, impulsivity and excessive motoric activity associated with ADHD. Methylphenidate and amphetamine-based stimulants are now available in longer-acting, once-daily and shorter-acting divided dosing schedules. Several nonstimulant, second-line treatments are now available or under development for the treatment of ADHD in children and adults. This article reviews the support for a variety of pharmacological agents and the issues to be considered when selecting an agent. The authors conclude that there is a need for additional direct comparisons between the longer-acting agents to effectively guide the practicing clinician.

Pharmacotherapy for excessive daytime sleepiness

Excessive daytime sleepiness (EDS) has recognized detrimental consequences such as road traffic accidents, impaired psychological functioning and reduced work performance. EDS can result from multiple causes such as sleep deprivation, sleep fragmentation, neurological, psychiatric and circadian rhythm disorders. Treating the underlying cause of EDS remains the mainstay of therapy but in those who continue to be excessively sleepy, further treatment may be warranted. Traditionally, the amphetamine derivatives, methylphenidate and pemoline (collectively sympathomimetic) psychostimulants were the commonest form of therapy for EDS, particularly in conditions such as narcolepsy. More recently, the advent of modafinil has broadened the range of therapeutic options. Modafinil has a safer side-effect profile and as a result, interest in this drug for the management of EDS in other disorders, as well as narcolepsy, has increased considerably. There is a growing school of thought that modafinil may have a role to play in other indications such as obstructive sleep apnea/hypopnea syndrome already treated by nasal continuous positive airway pressure but persisting EDS, shift work sleep disorders, neurological causes of sleepiness, and healthy adults performing sustained operations, particularly those in the military. However, until adequately powered randomised-controlled trials confirm long-term efficacy and safety, the recommendation of wakefulness promoters in healthy adults cannot be justified.

A case control study to examine the pharmacological factors underlying ventricular septal defects in the North of England

BACKGROUND

Amphetamine exposure is associated with congenital cardiac abnormalities in animals. We previously reported an association between recreational use of 2,4-methylenedioxymethamphetamine (ecstasy, MDMA) and ventricular septal defect in babies born to users. We have carried out a case control study to investigate risks in the occurrence of ventricular septal defect in a cohort of babies born in the North East of England.

METHODS

Cases were identified from paediatric cardiology units in Newcastle upon Tyne and Leeds, and controls were recruited from the mothers of babies born in the same hospital as the index case. Research nurses carried out interviews using a structured questionnaire.

RESULTS

A total of 296 case control pairs were studied. There was insufficient exposure to ecstasy to test the primary hypothesis. Increased risk of ventricular septal defect was found to be associated with consumption of cough and cold remedies [pre-conception OR 2.2, 95% CI 1.41, 3.51; pregnancy OR 5.1, 95% CI 2.56, 11.27; exposure in either OR 2.83, 95% CI 1.85, 4.45; P<0.005] and in the case of non-steroidals for exposures in pregnancy (OR 4.2, 95% CI 1.54, 14.26; P<0.005).

CONCLUSIONS

These findings suggest that ventricular septal defect is associated with consuming the medications identified. They are also compatible with the hypothesis that sympathomimetics (pseudoephedrine, phenylephrine and phenylpropanolamine) present in cough mixtures cause the increased risk, and with our original hypothesis that sympathomimetics and amphetamines are potentially cardiotoxic in utero.

Ergogenic aids: a review of basic science, performance, side effects, and status in sports

The use of drugs and supplements to enhance performance has become a part of mainstream athletics. Many team physicians and sports medicine practitioners are unfamiliar with the benefits and risks of these products and thus are unable to educate young athletes on this topic. In spite of numerous reports on the health risks of anabolic steroid use, 1 to 3 million Americans have used them. Human growth hormone has been tried by up to 5% of 10th graders, although no scientific study has shown that it is an effective performance-enhancing drug. Amphetamines and similar compounds may be the most widely abused drug in baseball; recently, they have come under increased scrutiny in sport. Erythropoietin is a highly effective aerobic enhancer that has been linked to multiple deaths in cyclists and other endurance athletes. The neutraceutical industry, led by supplements such as creatine, ephedra, and androstenedione, remains unregulated by the Food and Drug Administration and has serious issues with quality and side effects. An understanding of these products is essential for the sports medicine practitioner to provide sound, safe advice to the athlete.

Relationship between amphetamine ingestion and gingival enlargement

PURPOSE

The purpose of this study was to determine the relationship between amphetamine ingestion and gingival enlargement.

METHODS

A total of 40 subjects were included in this study. Group 1 consisted of 20 subjects taking amphetamines and attending the dental clinic at Children's Hospital of Buffalo and The University at Buffalo School of Dental Medicine. These subjects were not taking phenytoin, cyclosporine, or calcium channel blockers. Patients with cardiovascular or hormonal disorders were excluded from the study. The information obtained from patients' parents or legal guardians were: (1) the time when the patient started taking the medication; (2) how often the patient took the medication per day; and (3) the medication's dosage. Gingival and plaque indices were also measured to assess gingival health. The Silness and Löe plaque index and modified gingival index were used. A second group of 20 healthy subjects not taking any medications was used as a control group. Gingival enlargement was evaluated clinically by one examiner and evaluated from intraoral photographs by another examiner.

RESULTS

The results of this study demonstrated a relationship between amphetamine usage and gingival enlargement. There was a statistically significant increased prevalence (P<.05) of gingival enlargement in the group of patients taking amphetamines.

CONCLUSIONS

This study shows that patients taking amphetamines have an increased risk of gingival enlargement. A stringent effort to minimize gingival inflammation should be instituted, and patients should be monitored closely with more follow-up appointments than nonmedicated patients.

Tolerance to amphetamine hypophagia: a real-time depiction of learning to suppress stereotyped movements in the rat

To analyze how tolerance develops to amphetamine-induced hypophagia, the authors recorded real-time licking responses in rats given chronic injections of the drug and access to milk for 30 min. Initially, licking was greatly reduced and occurred only late in the session. The acquisition of tolerance was characterized by a decrease in the latency to initiate licking, a gradual increase in the number of licks, and a reorganization of the temporal licking pattern such that licks were distributed throughout the session, interspersed with pauses. On post-tolerance dose-response tests, licking was directly proportional to drug dose in some rats. The results support the view that tolerance to amphetamine hypophagia involves a behavioral adaptation to the motor effects of the drug.

Chemistry, Pharmacology, Toxicology, and Hepatic Metabolism of Designer Drugs of the Amphetamine (Ecstasy), Piperazine, and Pyrrolidinophenone Types

Designer drugs of the amphetamine type (eg, MDMA, MDEA, MDA), of the new benzyl or phenyl piperazine type (eg, BZP, MDBP, mCPP, TFMPP, MeOPP), or of the pyrrolidinophenone type (eg, PPP, MOPPP, MDPPP, MPPP, MPHP) have gained popularity and notoriety as rave drugs. These drugs produce feelings of euphoria and energy and a desire to socialize. Although in the corresponding drug scene designer drugs have the reputation of being safe, studies in rats and primates in combination with human epidemiologic investigations indicate potential risks to humans. Thus, a variety of adverse effects have been associated with the use/abuse of this class of drugs in humans, including a life-threatening serotonin syndrome, hepatotoxicity, neurotoxicity, and psychopathology. Metabolites were suspected to contribute to some of the toxic effects. Therefore, knowledge of the metabolism is a prerequisite for toxicologic risk assessment. The metabolic pathways, the involvement of cytochrome P450 isoenzymes in the main pathways, and their roles in hepatic clearance are described for designer drugs of different groups. In summary, polymorphically expressed CYP2D6 was the major enzyme catalyzing the major metabolic steps of the studied piperazine- and pyrrolidinophenone-derived designer drugs. However, it cannot be concluded at the moment whether this genetic polymorphism is of clinical relevance.

Schedules of controlled substances; placement of 2,5-dimethoxy-4-(n)-propylthiophenethylamine and N-benzylpiperazine into Schedule I of the Controlled Substances Act. Final rule

This final rulemaking is issued by the Acting Deputy Administrator of the Drug Enforcement Administration (DEA) to place 2,5-dimethoxy-4-(n)-propylthiophenethylamine (2C-T-7) and N-benzylpiperazine (BZP) into Schedule I of the Controlled Substances Act (CSA). This action by the DEA Acting Deputy Administrator is based on a scheduling recommendation by the Department of Health and Human Services (DHHS) and a DEA review indicating that 2C-T-7 and BZP meet the criteria for placement in Schedule I of the CSA. This final rule will continue to impose the regulatory controls and criminal sanctions of Schedule I substances on the manufacture, distribution, and possession of 2C-T-7 and BZP.

Amphetamine-induced chorea in attention deficit-hyperactivity disorder

Attention deficit-hyperactivity disorder (ADHD) is treated frequently with stimulants in both children and adults. While tics are occasional complications of stimulant therapy, chorea is reported rarely. We describe an adult ADHD patient who developed chorea upon dose escalation of mixed amphetamine salts, which resolved on discontinuation of the drug.

Cognitive impairment in substance abuse

Conventional wisdom, and even well-reasoned theoretical mechanisms, suggests that the chronic use of psychoactive substances would impair cognitive functioning of individuals. This article summarizes the research literature with regard to specific drugs of abuse. Undoubtedly, acute intoxication and immediate and protracted withdrawal produce transient alterations of cognitions that can persist for weeks to months. Some subtle residual effects remain for up to 1 year for certain drugs. Evidence of irreversible effects is less clear. Even subtle lingering effects can impact treatment efforts, yet they often go undetected or unaddressed.

Hidden amphetamines: from smoking cessation to diabetes

(1) Amphetamine-like drugs are not only authorised for use as appetite suppressants. (2) Bupropion, otherwise known as amfebutamone, is licensed as an aid to smoking withdrawal. It has amphetamine-like adverse effects, such as seizures; in addition it causes hypersensitivity reactions. (3) Benfluorex is sold in France as an adjunctive treatment for hypertriglyceridemia and diabetes with overweight. The lack of data on its adverse effects is hardly reassuring. A case of severe cardiac valve disease has been published. (4) The ephedrine derivatives norephedrine (phenylpropanolamine) and pseudoephedrine are used in ENT as decongestants because of their vasoconstrictive properties. They expose patients to serious cardiovascular risks. Ephedrine and plants belonging to the genus Ephedra (used in freshly prepared appetite suppressant mixtures) have negative risk-benefit ratios. (5) Methylphenidate is used as a psychostimulant in patients with narcolepsy and children with attention-deficit disorder. It can lead to serious mental and physical dependence.

The amphetamine appetite suppressant saga

(1) In 1999, all amphetamine derivatives still sold in France as appetite suppressants were withdrawn from the market because of serious cardiovascular adverse effects. Sibutramine, marketed in France since 2001, is closely related to this group of drugs. (2) The adverse effects shared by these drugs are mainly neuropsychiatric (due to a psychostimulant action) and cardiovascular (arterial hypertension and tachycardia). (3) More specific cardiovascular adverse effects, such as pulmonary hypertension and severe cardiac valve damage, emerged after several years of use. The first reports date back to the 1960s. (4) The pulmonary hypertension associated with appetite suppressants can be fatal or necessitate transplantation. (5) Cardiac valve damage due to appetite suppressants is generally irreversible and sometimes requires surgery.

[Primary pulmonary hypertension and its management]

Primary pulmonary hypertension (PPH) is a disease of un-known etiology that is characterized by an increase in pulmonary arterial pressure. Traditionally its treatment has been based on the administration of the vasodilator therapy with calcium channel blockers. At present there are some treatments which not only correct the vasoconstriction but also other pathogenic PPH associated effects, such a vascular remodelling and the thrombosis. These treatments include: a) analogs of prostacyclin with different administration routes; b) endothelin-receptor antagonists; and c) drugs that affect the metabolic pathway of nitric oxide. These pharmacological advances have reduced the number of pulmonary transplants in the patients with HPP, which is the last therapeutic alternative.